ENOVIS
Global medical technology company; orthopedic solutions
Material Handler - 2nd Shift
About the job
- A minimum of 0–1 years of experience is required.
- Data entry and computer knowledge, including Microsoft Outlook, Excel, Word, and PowerPoint, are required.
- A high school diploma is required.
- The employee must be able to sit, stand, or walk for up to 8 hours per day.
- The employee must be able to frequently carry up to 60 pounds for distances of up to 30 feet.
- The employee must have full range of motion of the waist and neck.
- The employee must have unrestricted use of the upper extremities and be able to perform overhead reaching.
- The employee must be able to frequently bend to the floor, twist, and kneel.
- The employee must be able to work in a non-temperature-controlled environment.
- Unpack and check received goods against purchase orders or invoices, and maintain records of received goods.
- Reject unsatisfactory, damaged, or defective items.
- Lift or move heavy items.
- Operate equipment to move materials to the proper department or storage location.
- Store materials in designated locations after receiving them in the system.
- Examine inventory and distribute materials and supplies to manufacturing lines.
- Monitor and control inventory integrity, and research inventory discrepancies.
- Prepare goods for final shipment and maintain records of shipped merchandise.
- Participate in the safety culture, audits, and the 5S program.
- Apply moderate knowledge of continuous improvement activities.
- Inform the supervisor or lead of work-related problems.
- Perform other duties as assigned.
- Effective communication and organizational skills, and the ability to work in a team-oriented environment.
About the company
Enovis develops medical devices and services to improve patient outcomes and restore mobility. It operates Prevention & Recovery with orthopedic braces, soft goods, vascular therapy, compression garments, and hot/cold therapy, and Reconstructive with joint implants and surgical tools such as Novastep. It differentiates itself through a broad clinically oriented portfolio, a global footprint, and the EGX continuous improvement program, plus the LimaCorporate acquisition expanding its transatlantic reach. Its goal is to provide better patient outcomes and mobility worldwide through sustained growth and operational excellence.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Wilmington, Delaware
Founded
2022
Get referred to ENOVIS
See people who can refer or advise you
Simplify's Take
What believers are saying
- Second-quarter 2026 orthopedic sales reached $582.8 million, up 3.2% year over year.
- Enovis entered a binding €155 million offer for eCential Robotics on August 31, 2026.
- ARVIS reached full U.S. commercial launch, and Nebula hips won competitive conversions.
What critics are saying
- Enovis disclosed unresolved SEC comments on 2024 and 2025 filings in February 2026.
- A 2025 third-party cloud incident forced Enovis to investigate, remediate, and notify records.
- eCential closing needs French works council approval; any delay pushes robotics revenue past 2028.
What makes ENOVIS unique
- ASTRA, ARVIS, and eCential create a broader orthopedic robotics stack.
- Enovis sells across reconstruction and bracing, reducing dependence on any single procedure type.
- LimaCorporate plus European brands give Enovis unusual transatlantic scale in orthopedics.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
Paid Vacation
Paid Sick Leave
Paid Holidays
Legal Services
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 30%Transient troubles shake up European market. by Mike Evers on September 15, 2026 The orthopedic market in Western Europe has shifted significantly over the last few years. In 2024, orthopedic procedure volumes were still rebounding from the disruption of the pandemic and Europe was driving significant growth. "The volumes outside the U.S. remain very strong, in particular in Europe," said Zimmer Biomet CEO Ivan Tornos in mid-2024. "Within Europe there is a prominent backlog. So, market dynamics are very healthy, more in EMEA than APAC, but very healthy overall." That strength persisted through much of 2025. Stryker called Europe a "growth engine" and said it had a huge opportunity to increase international penetration of the best-performing U.S. products. Both Medacta and Medartis saw their EMEA sales take off in the wake of the pandemic. CONMED's growth rate in EMEA has outpaced its growth rate in the United States over the last 10 years. Enovis used its aggressive M&A strategy to rapidly globalize and surpass $1 billion in annual reconstructive sales. In recent years, the company purchased European players like Mathys, Novastep and LimaCorporate. Today, international sales make up 53% of Enovis' total recon revenue. However, the European market has slowed significantly in 2026. "I would say it's more weighted to the transient," said Enovis CEO Damien McDonald. "Strikes, fires, heat waves, all of those things, we believe, are transient. Ultimately, you keep the patient in the funnel. The only thing for me is sentiment as the war in the Middle East continues, and what does that do as people reorient funding towards military spend versus health care. We haven't seen any of that read through, but that's the watch out." Below, Orthoworld'll take a look at some of the factors Mr. McDonald mentioned and how they're impacting the Western European orthopedic market. Strikes limit procedure capacity and extend wait times. European healthcare strikes and labor actions have come to a head due to wage disputes, staff shortages, burnout and rapidly rising demand. These factors are pushing up against government efforts to control healthcare costs. The U.K. experienced repeated resident doctor strikes, with the most recent action taking place in April 2026. The walkout cost the country an estimated £3 billion over the course of three years due to canceled procedures, rescheduling, overtime and higher-cost replacement staff. The procedure bottleneck in the U.K. goes beyond labor unrest. Highly specialized clinical roles are struggling to meet demand. A report from the Royal College of Anaesthetists estimated that staffing shortages were preventing 1.5 million procedures annually. Healthcare strikes in Spain are more variable and diffused across regions. In Rioja, for instance, strikes in 2026 caused the suspension of 39,000 consultations and 1,200 surgical procedures. More than 8,500 patients were awaiting surgery, and the average surgical wait time grew to 86 days. Orthopedic procedures are predominantly elective, and are therefore easily postponed. But, as Orthoworld saw during the pandemic, many of these patients remain in the funnel and eventually have their surgery done. However, not every orthopedic company is robust enough to withstand an extended downturn in procedure volume. Ongoing disruption in a market like Europe could have strategic implications for even the largest players. The Iran war impact is far-reaching. One of the most prevalent indirect impacts from the Iran war is the shock to energy prices. Oil prices are well above $100 per barrel in September of 2026. European natural gas prices have surged amid fears about Middle Eastern exports and winter storage. Increasing energy prices could further tax hospitals with already limited budget flexibility. The conflict has disrupted trade routes and increased transportation costs, which compound already inflated energy prices. In March, the World Health Organization warned that supply chain disruption can limit access to essential medicines and medical supplies. For orthopedic companies, the risk is spread across a wide array of categories including but not limited to polymer components, packaging, electronic components for robotics and navigation, as well as coatings and specialty materials. An increasingly unstable geopolitical climate has also caused defense spending in Europe to compete with limited fiscal space. There isn't a one-to-one trade-off between defense and healthcare, but Orthoworld is seeing some countries constrain healthcare spending while expanding defense spending. France's 2026 government budget included £5 billion in healthcare-related reductions or cost-containment measures, including higher deductibles, more oversight of long-term illness coverage and reductions in hospital operation costs. Per Le Monde, French public hospitals were already carrying a £3 billion deficit. Concurrently, France's 2026 fiscal plan called for £6.5 billion in additional defense spending. In the wake of Russia's invasion of Ukraine, Finland plans to increase defense spending despite ongoing austerity measures. The country intends to further cut healthcare and social services to reduce the fiscal deficit and rising public debt. Reuters reported that the healthcare and social services reductions were part of the fiscal consolidation program to facilitate increased defense spending. The picture in the U.K. and Germany is more nuanced. Defense spending is increasing, but not directly at the expense of healthcare. However, the expanded footprint of defense in budgets can crowd out other services and apply more pressure to patients as adjacent social services are reduced. The road ahead. Orthoworld agree with Mr. McDonald that these troubles are likely transient. Or, at least, some of them are. Fiscal policy isn't something that can change overnight. Orthoworld learned during the period from 2020 to 2022 that orthopedic patients tend to be sticky. They defer procedures for a long time, but ultimately, they return since they're not going to get better otherwise. Companies that can demonstrate greater efficiency in the operation room and provide better value-based solutions will have a strategic advantage in the European market of the near future. Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Zimmer Biomet announces Americas leadership promotions to accelerate commercial transformation. Sep 08, 2026, 16:30 ET Gary Campbell promoted to President, Americas Brian Hatcher promoted to President, Recon, S.E.T., CMFT, Neuro and Biosurgery Bradley Kessler promoted to President, Americas - Robotics, Technology and Data WARSAW, Ind., Sept. 8, 2026 /PRNewswire/ - Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced leadership appointments designed to streamline its Americas and Global Business Group organizations for greater focus and agility. Effective October 1, Gary Campbell will be promoted to President, Americas, and Brian Hatcher will be promoted to President, Recon, S.E.T., CMFT, Neuro and Biosurgery. The company also announced the promotion of Bradley Kessler to President, Americas - Robotics, Technology and Data. Campbell, Hatcher and Kessler will report directly to Ivan Tornos, Chairman, President and CEO of Zimmer Biomet. "We talk often about our People and Culture strategic imperative to have the right talent, in the right roles, at the right times," said Tornos. "These well-deserved promotions do exactly that, while helping to accelerate our U.S. go-to-market transformation and sharpen ownership of our most important commercial priorities. Gary, Brian and Brad are seasoned operators and proven Zimmer Biomet leaders with deep experience in the businesses and markets they will now lead. Their promotions reinforce my strong confidence in both our 2026 outlook and our growth potential in 2027 and beyond." As part of this restructuring, Kevin Thornal, Group President, Global Businesses and the Americas, will leave the company on September 30, 2026, following a transition period. Tornos added, "On behalf of the entire Zimmer Biomet team, I want to thank Kevin for his leadership and contributions to our company. We wish him all the best in his next chapter." 2026 Outlook Zimmer Biomet also announced today that the Company is reiterating its full-year 2026 financial outlook provided on August 5, 2026. About Gary Campbell As President, Americas, Campbell will be responsible for commercial strategy and execution across the United States, Canada and Latin America. He will continue to lead the evolution of the company's U.S. go-to-market model, building a specialized and dedicated organization designed to increase productivity and accelerate growth. Campbell has served as Zimmer Biomet's vice president and general manager, Orthopedics - North America since September 2024. Since joining the company in 2019, Campbell has held multiple commercial leadership roles of increasing responsibility. Previously, Campbell served in several sales and marketing roles at Enovis. He holds a bachelor's degree from Texas State University. About Brian Hatcher As President, Recon, S.E.T., CMFT, Neuro and Biosurgery, Hatcher will lead global portfolio strategy and execution across most of the company's businesses, expanding his current remit to include Global Knees and Hips. He will continue to play an integral role in the company's innovation and diversification strategy, including delivering organic and inorganic opportunities in higher growth markets. Lou Galrao, President of Reconstruction (Knees and Hips), will report to Hatcher. During his 16-year career with Zimmer Biomet, Hatcher has held multiple roles in research, marketing, general management and business leadership. He was named to his first Global President role in 2021 and currently serves as Zimmer Biomet's President of S.E.T. and CMFT. Hatcher began his medical technology career with roles at OrbusNeich and later Medtronic. He holds a bachelor's degree in chemistry and a Ph.D. in biomedical engineering, both from the University of Florida. About Brad Kessler As President, Americas - Robotics, Technology and Data, Kessler will be responsible for driving commercial strategy, growth and adoption of the company's broad portfolio of robotics, digital and technology solutions in the Americas, as well as its global service and capital solutions contracting business. Under Kessler's leadership, the company will accelerate the expansion of its specialized robotics salesforce in advance of the highly anticipated launch of the Monogram next-generation orthopedic robot, which is expected in 2027. Kessler brings to the role more than two decades of commercial experience in orthopedics. Currently vice president and general manager, Robotics, Technology and Data Solutions, Kessler has held multiple commercial leadership roles of increasing responsibility since he joined Zimmer Biomet in 2015. Prior to joining Zimmer Biomet, Kessler spent nearly 10 years in sales at Stryker. He holds a bachelor's degree from Texas A&M University and an Executive MBA from the Cox School of Business at Southern Methodist University. About Zimmer Biomet Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation. Cautionary Note Regarding Forward-Looking Statements This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning Zimmer Biomet's expectations, plans, outlook, prospects, and product and service offerings, including new product launches and potential clinical successes. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially. For a list and description of some of such risks and uncertainties, see Zimmer Biomet's periodic reports filed with the U.S. Securities and Exchange Commission ("SEC"). These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet's filings with the SEC. Forward-looking statements speak only as of the date they are made, and Zimmer Biomet disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this news release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this news release. | Contacts: Media Troy Kirkpatrick 614-284-1926 [email protected] Kirsten Fallon 781-779-5561 [email protected] | Investors David DeMartino 646-531-6115 [email protected] Zach Weiner 908-591-6955 [email protected] | SOURCE Zimmer Biomet Holdings, Inc.
Enovis has entered a binding offer to acquire eCential Robotics, a developer of surgical robotics and enabling technologies, for an upfront enterprise value of €155 million. The deal includes approximately €176 million in cash to shareholders at closing, plus up to €35 million in contingent consideration tied to milestones. The transaction, expected to close by year-end 2026, will expand Enovis' ASTRA platform with robotic automation capabilities. The acquisition will be funded through cash and Enovis' existing revolving credit facility. Enovis anticipates 100 basis points of adjusted EBITDA margin headwind in 2027, with free cash flow conversion expected to reach 50% that year, exceeding $100 million. The deal will establish a robotics centre of excellence in Grenoble, France. The transaction remains subject to regulatory approvals and French works council procedures.
Enovis targets robotic surgery expansion with €155M eCential Robotics deal. September 1, 2026 Key points. * Enovis has made a binding offer to acquire eCential Robotics for an enterprise value of €155 million, with up to €35 million in milestone payments. The deal is expected to close by the end of 2026 and will be funded with cash and revolving-credit capacity. * The acquisition expands Enovis' ASTRA ecosystem into robotics, with plans to launch a next-generation platform for total knee procedures within two years and pursue a shoulder application afterward. Initial commercial contributions are expected in 2028. * Enovis expects the deal to temporarily dilute adjusted EBITDA margins by roughly 100 basis points in 2027 after underlying improvements, while leverage rises by about half a turn. The company still targets at least $100 million in free cash flow next year and expects margin benefits as robotics sales develop. * MarketBeat previews the top five stocks to own by October 1st. Enovis NYSE: ENOV said it has entered a binding offer to acquire eCential Robotics, a developer of surgical robotics technology, in a move the orthopedic company said will expand its enabling-technology capabilities and accelerate its pathway into robotic surgery. Chief Executive Officer Damien McDonald said the proposed acquisition is intended to supplement Enovis' existing ASTRA ecosystem of planning and navigation technologies. The company aims to offer surgeons a connected platform spanning planning, navigation and robotic capabilities across hospitals, outpatient clinics and ambulatory surgery centers. "The eCential transaction is more than just a robot," McDonald said. "It is a deliberate strategy to reinforce Enovis' growth trajectory with a credible long-term position in robotics and advanced enabling tech." Transaction terms and timeline. Chief Financial Officer Ben Berry said the initial upfront consideration is based on an enterprise value of €155 million, representing about €176 million in cash to be paid to eCential shareholders at closing. The agreement also includes up to €35 million in contingent payments tied to development milestones for knee and shoulder product introductions. Enovis expects the deal to close by the end of 2026, subject to customary regulatory approvals. The company plans to finance the acquisition through cash on hand and available capacity under its revolving credit facility. Berry said the transaction would initially add about one-half turn to leverage. Enovis reduced leverage to 3.1 times from 3.8 times over the preceding 12 months and expects to return to roughly 3 times leverage by the end of 2027. Robotics development plans. Enovis said it plans to bring a next-generation robotic platform to market within two years, starting with total knee procedures. The company expects an initial commercial contribution beginning in 2028, according to its remarks. A shoulder application is expected to follow. McDonald said eCential brings more than 50 employees with experience designing, developing and supporting the launch of three robotic platforms across orthopedics and spine. Group President of Reconstructive Louie Vogt said the Grenoble-based team is primarily focused on software and hardware engineering, with quality, regulatory, manufacturing and assembly capabilities. He said its current assembly output is estimated at 75 to 100 robots annually. For knee surgery, Enovis said it will develop planning capabilities that use CT imaging to create a virtual surgical application and the software foundation that will drive the robot. Vogt said the company also intends to incorporate surgeon and key opinion leader input into the product-development process. In shoulder procedures, Enovis sees an opportunity to develop a more differentiated offering. McDonald said the company has significant global market share in total shoulder arthroplasty and believes a robotic arm with seven degrees of freedom could differentiate its platform. Vogt said Enovis already has shoulder planning and navigation capabilities, while robotic shoulder surgery remains a relatively early market. eCential's proprietary robotic control layer is expected to integrate with Enovis' AI-enabled planning and navigation technology, the company said. Vogt said Enovis intends to use a unified portal, navigation core, camera tracking, software code base, workflow and user interface across ASTRA ARVIS and the future robotics platform. Commercial strategy and spine operations. Vogt said Enovis expects to use a hybrid commercial model, augmenting its distributor channel with corporate resources ranging from enterprise-solutions personnel to clinical success managers. The company has begun building related capabilities through the rollout of its ARVIS ecosystem. For ambulatory surgery centers, Vogt said Enovis expects to tailor its offering based on an account's procedure volume and economic needs. He said company research suggests that facilities performing fewer than 100 knee procedures annually may not be well suited to a large-format robot, though he noted that this would not apply in every case. ARVIS is expected to remain part of the company's approach for accounts with different requirements. eCential currently has a spine solution and has developed Johnson & Johnson's Velys spine robot, McDonald said. However, Enovis said it does not intend to enter the surgical spine market. It plans to support eCential's existing spine agreements and relationships while focusing its own development efforts on knee and shoulder applications. Margin and cash flow expectations. Berry said Enovis expects the acquisition to create approximately 150 basis points of adjusted EBITDA margin dilution in 2027, partly offset by about 50 basis points of underlying improvement, for a net headwind of roughly 100 basis points. The company attributed most of the dilution to the operating expenses and infrastructure acquired with eCential, along with additional investment to accelerate product development. Enovis expects 50 basis points of year-over-year underlying margin improvement in 2028. It said initial commercial traction should begin offsetting operating costs in mid-2028, with 100 basis points of margin improvement anticipated in 2029. Despite the planned investment, Enovis reaffirmed its expectation for free-cash-flow conversion of about 50% in 2027 and committed to generating at least $100 million in absolute free cash flow next year. The company expects free-cash-flow conversion to rise to approximately 70% in 2029. About Enovis (NYSE:ENOV). Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation. The company's flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Enovis, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enovis wasn't on the list. While Enovis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Enovis makes binding offer to acquire eCential Robotics - unite.ai. Enovis Corporation has entered a binding offer to acquire eCential Robotics, a French developer of surgical navigation and robotic-assistance systems, at an upfront enterprise value of €155 million, the companies announced on September 1, 2026. The transaction is expected to close by year-end 2026, subject to regulatory approvals. Under the terms described in the announcement, the €155 million enterprise value corresponds to cash consideration of approximately €176 million to be paid to eCential Robotics' shareholders at closing, plus up to €35 million in contingent consideration payable if certain milestones are achieved. Enovis plans to fund the proposed transaction through a combination of cash on its balance sheet and availability under its existing revolving credit facility. The binding offer was entered into on August 31, 2026, according to a current report Enovis filed with the U.S. Securities and Exchange Commission. Because eCential Robotics is a French company, the parties must first complete an information and consultation process with eCential Robotics' works council in accordance with French law. Following that process, the parties expect to enter into a definitive acquisition agreement. A robotic platform built for the operating room. Founded on more than 15 years of work in computer-assisted surgery and orthopedic robotics, eCential Robotics has developed a modular platform that combines surgical navigation and active robotics in a single architecture. According to the company's own description, the Op.n platform is an open, modular, and scalable system that integrates real-time spine navigation, robotic guidance, and operating room 3D imaging, and it is designed to support both open and minimally invasive spinal fusion procedures. The platform's regulatory foundation is established. The Op.n platform holds FDA 510(k) clearance for spine surgery in the United States, and eCential Robotics received a further 510(k) clearance for the latest generation of the platform in March 2025, according to the company. Its system first obtained FDA certification covering imaging, navigation, and the robotic arm in 2022, and the company performed its first robotic surgery in 2024. eCential Robotics is headquartered in Gières, France, with U.S. commercial operations in Franklin, Tennessee. The company opened its U.S. headquarters in Franklin in 2025. Its origins trace to 2009, when founder Stéphane Lavallée created the company then known as Surgivisio in Grenoble; the business adopted the eCential Robotics name in 2021. In 2024, the company gained industry visibility through a collaboration with DePuy Synthes on the Velys Spine robotic system, and in 2026 its partner Amplitude Surgical performed a first robotic knee surgery powered by eCential Robotics technology. Where eCential fits inside Enovis. Enovis said the acquisition will expand its ASTRA enabling technology platform with robotic automation capabilities. The company described eCential Robotics' robotics platform as a natural complement to its ARVIS Augmented Reality System, and said the combination is intended to give surgeons a broader set of robotic solutions. "This acquisition is a significant milestone and reflects our disciplined approach to bringing externally developed innovation into Enovis," said Damien McDonald, Chief Executive Officer of Enovis. "Their expertise will serve as the bedrock of our robotics strategy and enable Enovis to win in surgical enabling technology." Clément Vidal, Chief Executive Officer of eCential Robotics, said the company's strategy has centered on offering surgeons easy-to-use technology to improve surgical workflows and patient outcomes. "As part of Enovis, we will be able to grow through a shared mission to support surgeons with greater operating room efficiency, and help patients live more full, active lives," he said. Stéphane Lavallée, Founder and Chair of eCential Robotics, said the combined companies will continue to support existing partnerships and build a center of excellence for robotics in Grenoble focused on advancing the shared innovation roadmap. Enovis highlighted that planned Grenoble robotics center of excellence in its announcement, describing the city as a talent-rich medical technology hub. eCential Robotics said it remains committed to supporting collaboration with spine implant partners in the deployment of its newly FDA-cleared Op.n Spine Navigation and Robotic Guidance Platform. Financial expectations and next steps. Enovis said it expects approximately 150 basis points of deal-related dilution to its adjusted EBITDA margin in 2027, offset by approximately 50 basis points of underlying improvement, which the company described as a 100-basis-point headwind in 2027. The company said it expects to return to year-over-year margin improvement in 2028, and that it expects free cash flow conversion to increase to 50 percent in 2027, to over $100 million, with further improvement in 2028 and 2029. Enovis hosted an investor conference call and webcast at 8:30 a.m. Eastern time on September 1, 2026, to discuss the transaction, according to the SEC filing. Latham & Watkins LLP is serving as legal counsel to Enovis in connection with the transaction. Apparius is acting as exclusive financial advisor to eCential Robotics, with Goodwin France and Cabinet Franck Robert serving as legal counsel. The companies expect the transaction to close by the end of 2026, subject to regulatory approvals and completion of the works council consultation process.